RU2016106583A3 - - Google Patents

Download PDF

Info

Publication number
RU2016106583A3
RU2016106583A3 RU2016106583A RU2016106583A RU2016106583A3 RU 2016106583 A3 RU2016106583 A3 RU 2016106583A3 RU 2016106583 A RU2016106583 A RU 2016106583A RU 2016106583 A RU2016106583 A RU 2016106583A RU 2016106583 A3 RU2016106583 A3 RU 2016106583A3
Authority
RU
Russia
Application number
RU2016106583A
Other languages
Russian (ru)
Other versions
RU2016106583A (ru
RU2693487C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016106583A publication Critical patent/RU2016106583A/ru
Publication of RU2016106583A3 publication Critical patent/RU2016106583A3/ru
Application granted granted Critical
Publication of RU2693487C2 publication Critical patent/RU2693487C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2016106583A 2013-08-07 2014-08-07 Пептиды, способные реактивировать мутанты р53 RU2693487C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862977P 2013-08-07 2013-08-07
US61/862,977 2013-08-07
PCT/IB2014/063777 WO2015019318A1 (en) 2013-08-07 2014-08-07 Peptides capable of reactivating p53 mutants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019119609A Division RU2721423C2 (ru) 2013-08-07 2014-08-07 Пептиды, способные реактивировать мутанты р53

Publications (3)

Publication Number Publication Date
RU2016106583A RU2016106583A (ru) 2017-08-30
RU2016106583A3 true RU2016106583A3 (enExample) 2018-03-29
RU2693487C2 RU2693487C2 (ru) 2019-07-03

Family

ID=52460737

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2019119609A RU2721423C2 (ru) 2013-08-07 2014-08-07 Пептиды, способные реактивировать мутанты р53
RU2016106583A RU2693487C2 (ru) 2013-08-07 2014-08-07 Пептиды, способные реактивировать мутанты р53

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2019119609A RU2721423C2 (ru) 2013-08-07 2014-08-07 Пептиды, способные реактивировать мутанты р53

Country Status (12)

Country Link
US (4) US9856289B2 (enExample)
EP (1) EP3030571B1 (enExample)
JP (2) JP6554099B2 (enExample)
CN (1) CN105579464B (enExample)
AU (2) AU2016200713B2 (enExample)
BR (1) BR112016002721A2 (enExample)
CA (1) CA2920147C (enExample)
ES (1) ES2795982T3 (enExample)
HU (1) HUE049292T2 (enExample)
IL (2) IL243944B (enExample)
RU (2) RU2721423C2 (enExample)
WO (1) WO2015019318A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049292T2 (hu) 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
CN105112377B (zh) * 2015-09-25 2018-10-30 福州迈新生物技术开发有限公司 一株分泌抗p53单克隆抗体的杂交瘤细胞株及其应用
CA3012302A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
KR20250024096A (ko) 2017-09-29 2025-02-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 p53을 인식하는 t 세포 수용체
EA202091396A1 (ru) 2017-12-07 2020-09-02 РИВЕН АйПи ХОЛДКО ЭлЭлСи Композиции и способы лечения метаболических состояний
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
WO2019134650A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Mp53 rescue compounds and methods of treating a p53 disorder
EP3982947A1 (en) * 2019-06-12 2022-04-20 Reven IP Holdco LLC Methods and compositions for improving outcomes of cancer patients
JP7402026B2 (ja) 2019-11-27 2023-12-20 株式会社小松製作所 作業機械の制御システム、作業機械、作業機械の制御方法
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
CN111574591B (zh) * 2020-04-29 2021-09-21 西安交通大学医学院第一附属医院 一种多肽及其合成方法
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
US20230049952A1 (en) * 2020-06-24 2023-02-16 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
US20250052762A1 (en) * 2020-12-21 2025-02-13 Alaunus Biosciences, Inc. Peptidase cleavable substrates and methods of identification and use thereof
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法
CN115466786A (zh) * 2021-06-11 2022-12-13 上海交通大学医学院附属瑞金医院 一种筛选适合用p53复活药物治疗p53异常相关疾病病人的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) * 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
EP0989136A4 (en) * 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk PEPTIDES WITH CYCLIC STRUCTURES THAT CAN RECOVER THE ACTIVITY OF MUTED P53 PROTEINS.
US20030224379A1 (en) * 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
AU2002256985B8 (en) 2001-01-26 2008-03-20 Inhibitex, Inc Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
WO2002068601A2 (en) * 2001-02-28 2002-09-06 Skubitz Keith M Small peptides capable of modulating the function of cd66 (ceacam) family members
US20070128657A1 (en) * 2002-01-23 2007-06-07 El-Gewely Mohamed R Molecular libraries
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
WO2007149062A2 (en) * 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
WO2009094006A2 (en) * 2007-10-25 2009-07-30 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
US8822420B2 (en) * 2008-03-13 2014-09-02 Universita Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
SG11201401043SA (en) * 2011-09-09 2014-08-28 Agency Science Tech & Res P53 activating peptides
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US9657064B2 (en) * 2012-09-13 2017-05-23 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
HUE049292T2 (hu) 2013-08-07 2020-09-28 Yeda Res & Dev A P53 mutánsok újraaktíválására képes peptidek
CA3012302A1 (en) 2016-02-04 2017-08-10 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53

Also Published As

Publication number Publication date
RU2019119609A3 (enExample) 2019-12-30
US20160215019A1 (en) 2016-07-28
CN105579464A (zh) 2016-05-11
HUE049292T2 (hu) 2020-09-28
RU2721423C2 (ru) 2020-05-19
AU2016200713B2 (en) 2017-02-02
US10336789B2 (en) 2019-07-02
WO2015019318A1 (en) 2015-02-12
RU2019119609A (ru) 2019-08-07
EP3030571A4 (en) 2017-05-10
AU2017202806A1 (en) 2017-05-18
CN105579464B (zh) 2021-01-26
IL268355A (en) 2019-09-26
US20200095282A1 (en) 2020-03-26
JP2016527891A (ja) 2016-09-15
US10550152B2 (en) 2020-02-04
US9856289B2 (en) 2018-01-02
AU2017202806B2 (en) 2018-04-05
US11028127B2 (en) 2021-06-08
BR112016002721A2 (pt) 2018-07-10
EP3030571B1 (en) 2020-03-18
HK1219742A1 (en) 2017-04-13
IL243944A0 (en) 2016-04-21
IL243944B (en) 2019-08-29
EP3030571A1 (en) 2016-06-15
AU2016200713A1 (en) 2016-05-19
US20180057533A1 (en) 2018-03-01
JP2019214573A (ja) 2019-12-19
CA2920147A1 (en) 2015-02-12
CA2920147C (en) 2022-09-20
RU2016106583A (ru) 2017-08-30
US20190315804A1 (en) 2019-10-17
RU2693487C2 (ru) 2019-07-03
JP6554099B2 (ja) 2019-07-31
ES2795982T3 (es) 2020-11-25

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112015007533A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014018502A2 (enExample)
BR112014017739A2 (enExample)
BR112014019326A2 (enExample)
BR112014018480A2 (enExample)
BR112014018516A2 (enExample)
BR112014020341A2 (enExample)
BR112014017855A2 (enExample)
BR112014017765A2 (enExample)
BR112014017669A2 (enExample)
BR112014021878A2 (enExample)
RU2019119609A3 (enExample)
BR112014018468A2 (enExample)
BR112014017901A2 (enExample)
BR112014019204A2 (enExample)
BR112014018207A2 (enExample)
BR112015015948A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112014018578A2 (enExample)
BR112014018483A2 (enExample)
BR112014017794A2 (enExample)